Although the scientific and clinical relevance of these findings require both the analysis of more clinical specimens and the exploration of the mechanism underlying E2F7 nucleocytoplasmic shuttling, such efforts may eventually lead to the development of novel targeted therapies for GC. This evidence concerns the gene E2F7 and gastric cancer.